Multiple Sclerosis Clinical Trial

Entire-body PET Scans for Multiple Sclerosis

Summary

To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.

View Full Description

Full Description

To collect exploratory data using the most recent PET-CT scanners with their increased detection sensitivity and spatial resolution for the evaluation of F18-florbetapir radiopharmaceutical uptake in the nervous system of the entire body with special attention to correlation of radiotracer activity levels in the myelinated, demyelinated, or remyelinated white matter of multiple sclerosis (MS) patients compared to normal healthy subjects. The pilot study will be conducted on 20 participants as a clinical research trial of PET amyloid and myelin imaging with the primary objective of identifying possible differences in F18-florbetapir radiotracer activity for MS patients compared to normal healthy subjects, and the secondary objective of monitoring psychological health of those participants who elect to be informed of imaging results and who complete a panel of psychometric scales before and after imaging results disclosure.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Multiple sclerosis (MS) patients diagnosed by a credentialed neurologist experienced with care of multiple sclerosis patients.
Normal healthy subjects.
Willing and able to lie motionless on the PET-CT scanner bed for at least 10 minutes and up to 20 minutes for the duration of the PET-CT medical imaging scan.

Exclusion Criteria:

Any additional complicating medical illness other than MS including any other neuropsychiatric illness unrelated to MS diagnosed prior to the onset of initial symptoms of MS.
Pregnancy or breast feeding.
Diabetes or other metabolic-endocrine disorders.
Any known concomitant acute infection.
History of metastatic or locally invasive cancer.
Recent surgery, chemotherapy or radiation therapy.

Study is for people with:

Multiple Sclerosis

Phase:

Early Phase 1

Estimated Enrollment:

20

Study ID:

NCT04390009

Recruitment Status:

Recruiting

Sponsor:

Brain Health Alliance

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Brain Health Alliance
Ladera Ranch California, 92694, United States More Info
Carl Taswell, MD, PhD
Contact
949-481-3121
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Early Phase 1

Estimated Enrollment:

20

Study ID:

NCT04390009

Recruitment Status:

Recruiting

Sponsor:


Brain Health Alliance

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider